You are here

Coronary Intervention & Surgery

 

Older adults with atrial fibrillation who underwent left atrial appendage occlusion (LAAO) at the time of cardiac surgery had an approximately 40 percent reduction in thromboembolism and a 15 percent reduction in all-cause mortality, according to a database analysis.

A randomized study found that using two FDA-approved cerebral embolic protection devices in patients undergoing surgical aortic valve replacement (SAVR) was not associated with an improvement in freedom from clinical or radiographic infarction or clinical stroke.

At 12 months, patients with stable angina or acute coronary syndrome had similar rates of major adverse cardiac events whether they underwent revascularization guided by instantaneous wave-free ratio (iFR) or fractional flow reserve (FFR), according to a randomized, registry-based trial.

Patients with chronic total occlusions (CTOs) had similar results whether they underwent PCIs or received optimal medical treatment, according to a prospective, open-label, randomized trial.

After reviewing data from a clinical trial, the FDA issued a letter to healthcare providers informing them that patients who received the Absorb bioresorbable vascular scaffold had an increased rate of major adverse cardiac events compared with patients treated with the Xience drug-eluting stent.

 

Recent Headlines

ACC.17: LAAO at the time of cardiac surgery may reduce thromboembolism, mortality

Older adults with atrial fibrillation who underwent left atrial appendage occlusion (LAAO) at the time of cardiac surgery had an approximately 40 percent reduction in thromboembolism and a 15 percent reduction in all-cause mortality, according to a database analysis.

ACC.17: Levosimendan improves outcomes for heart surgery patients

Levosimendan, a drug used to prevent heart failure during heart surgery, was shown to not reduce adverse outcomes in patients at a high risk for low cardiac output syndrome in a new study debuted at the American College of Cardiology’s 66th Annual Scientific Session.

ACC.17: ABSORB III trial shows stent associated with increased risk of adverse outcomes

New results on Abbott Vascular’s Absorb everolimus-eluting bioresorbable vascular scaffold (BVS) were revealed at this year’s American College of Cardiology (ACC)’s Scientific Session, providing disappointing results for the stent that are consistent with a trend set by previous studies.

ACC.17: Cerebral embolic protection devices may not improve freedom from stroke, infarction

A randomized study found that using two FDA-approved cerebral embolic protection devices in patients undergoing surgical aortic valve replacement (SAVR) was not associated with an improvement in freedom from clinical or radiographic infarction or clinical stroke.

ACC.17: Revascularization strategies guided by FFR, iFR have similar adverse cardiac event rates

At 12 months, patients with stable angina or acute coronary syndrome had similar rates of major adverse cardiac events whether they underwent revascularization guided by instantaneous wave-free ratio (iFR) or fractional flow reserve (FFR), according to a randomized, registry-based trial.

ACC.17: Patients with CTOs have similar outcomes with PCIs, optimal medical treatment

Patients with chronic total occlusions (CTOs) had similar results whether they underwent PCIs or received optimal medical treatment, according to a prospective, open-label, randomized trial.

FDA warns of increased major adverse cardiac events with the Absorb dissolving stent

After reviewing data from a clinical trial, the FDA issued a letter to healthcare providers informing them that patients who received the Absorb bioresorbable vascular scaffold had an increased rate of major adverse cardiac events compared with patients treated with the Xience drug-eluting stent.

Ischemia, bleeding increase mortality risk in patients a year after coronary stenting

Patients who had ischemic and bleeding events 12 to 33 months after undergoing coronary stenting had an increased mortality risk, according to a post hoc analysis of a randomized study.

CMS approves two more facilities to perform carotid artery stenting for high risk patients

Since the beginning of the year, CMS has approved two facilities for performing carotid artery stenting for high risk patients.

Study examines treatments for atrial fibrillation patients following PCI with stenting

Daiichi Sankyo Company announced on March 6 that the first patient had enrolled in a Phase 3b study evaluating edoxaban (Savaysa) versus a vitamin K antagonist in patients with atrial fibrillation following PCI with stenting.

Pages